MIMOSA Diagnostics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, MIMOSA Diagnostics sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

MIMOSA Diagnostics: 1 sponsored US clinical trial, 1 recruiting.

MIMOSA Diagnostics sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Vascular Disease, Peripheral, with 1 trials.

Mid-pack sponsor footprint

MIMOSA Diagnostics is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING

Correlating Multispectral Near-Infrared Imaging to Standard Vascular Diagnostics

NCT06899113

Therapeutic Areas

Vascular Disease, Peripheral 1
Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer) 1

What is open in the MIMOSA Diagnostics pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Vascular Disease, Peripheral (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

MIMOSA Diagnostics: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

MIMOSA Diagnostics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share MIMOSA Diagnostics1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
MIMOSA Diagnostics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

MIMOSA Diagnostics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this MIMOSA Diagnostics page

1 registered trials is a research-attention snapshot, not an endorsement of MIMOSA Diagnostics or any single study.

  • 1 of MIMOSA Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Vascular Disease, Peripheral is the condition MIMOSA Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Vascular Disease, Peripheral trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

MIMOSA Diagnostics pipeline card: 1 registered trials from official public datasets.Report a data error.